Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 7Withdrawn 4Terminated 4Suspended 2Recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell, Peripheral 1

Interventions

Drug Therapy 107Cisplatin 97Radiotherapy 89Carboplatin 87Bevacizumab 79Oxaliplatin 74tislelizumab 68Capecitabine 68Gemcitabine 64Cyclophosphamide 64toripalimab 62Paclitaxel 57pembrolizumab 55sintilimab 53Specimen Handling 53Surgical Procedures, Operative 52anlotinib 49Fluorouracil 49Magnetic Resonance Spectroscopy 48Immune Checkpoint Inhibitors 43Blood Specimen Collection 42130-nm albumin-bound paclitaxel 42Standard of Care 38camrelizumab 36fludarabine 35lenvatinib 34Leucovorin 34venetoclax 30Radiosurgery 30Immunotherapy 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × OTHER × tazemetostat × Clear all
NCT07209163 2025-10-06

Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma

Ruijin Hospital

Phase 1/2 Not yet recruiting
48 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡